Bristol-Myers Squibb: Index
 
Global Reporting Initiative Content Index

The Bristol-Myers Squibb sustainability website is a GRI-based report. We believe we are among the first companies to issue a GRI-based report, following the criteria in the Global Reporting Initiative (GRI) 2006 G3 Sustainability Reporting Guidelines.

The GRI Application Level grid (below) is included in this report to support our Application Level B+. A copy of the GRI G3 Application Level Check detailing the fulfillment of Application Level B+ is available here. An independent third-party review of this website confirms that it meets the content and quality requirements of GRI G3 Application Level B+.


Report Application Level C B A
(C+ = Report
Externally Verified)
(B+ = Report
Externally Verified)
(A+ = Report
Externally Verified)
G3 Profile Disclosures Report on: 1.1, 2.1-2.10, 3.1-3.8, 3.10-3.12, 4.1-4.4, 4.14-4.15

Report on all criteria listed for Level C plus: 1.2, 3.9, 3.13, 4.5-4.13, 4.16-4.17

Same as requirement for Level B
G3 Management Approach Disclosures Not Required Management Approach Disclosures for each Indicator Category Management Approach Disclosures for each Indicator Category
G3 Performance Indicators and Sector Supplement Performance Indicators Report on a minimum of 10 Performance Indicators, including at least one from each of: social, economic, and environmental Report on a minimum of 20 Performance Indicators, including at least one from each of: economic, environmental, human rights, labor, society, product responsibility Respond on each core G3 and Sector Supplement indicator with due regard to the materiality principle by either: a) reporting on the indicator or b) explaining the reason for its omission

We are interested in your feedback. Please send us your comments on the GRI Content Index below and our self-declaration as a GRI-based report.

The following index is designed for stakeholders who are familiar with the Global Reporting Initiative (GRI) 2006 G3 Sustainability Reporting Guidelines. For each G3 performance indicator below, we include a link to the pertinent section of the Bristol-Myers Squibb sustainability website.


GRI
Indicator
Description Location within www.bms.com/sustainability
1. Strategy and Analysis
1.1 Statement from senior decision-maker CEO Message
1.2 Description of key impacts, risks, and opportunities Sustainability Issues

2. Organizational Profile
2.1 Organization's name Key Facts
2.2 Major products Key Facts
2.3 Operational structure and major divisions Key Facts
Our Partners and Leadership
2.4 Location of headquarters New York, New York, USA
2.5 Countries of operation Economic Responsibility
Economic Performance
Facility Information
2.6 Nature of ownership Key Facts
Economic Responsibility
2.7 Markets served including geographic breakdown/sectors served/customers Economic Responsibility
Economic Performance
2.8 Scale of organization including number of employees, nets sales/revenues, total capitalization Key Facts
Economic Performance
Key Performance Indicators
2012 Annual Report, page 7
2.9 Significant changes during reporting period A Brief History of Bristol-Myers Squibb
2.10 Awards Awards & Recognition

3. Report Parameters
3.1 Reporting period About this Report– Reporting Period and Scope
3.2 Date of previous report About this Report– Reporting Period and Scope
3.3 Reporting cycle About this Report– Reporting Period and Scope
3.4 Contact point About this Report– Contact Point for Questions
3.5 Process for defining report content About this Report– Defining Report Content
Sustainability Issues
Stakeholder Engagement
3.6 Boundary of the report About this Report– Reporting Period and Scope
3.7 Limitations on the scope or boundary of the report About this Report– Reporting Period and Scope
3.8 Basis for reporting on joint ventures, etc. About this Report– Reporting Period and Scope
3.9 Data measurement techniques and bases of calculations including assumptions Process for Data Collection
Environmental Performance
Energy
Climate Change and Greenhouse Gas Emissions
Other Air Emissions
Waste
Safety
3.10 Restatements of information About this Report– Changes in Reporting
3.11 Significant changes from previous reporting periods About this Report– Changes in Reporting
3.12 GRI Content Index table Global Reporting Initiative Content Index
3.13 Policy and practice for seeking independent assurance for report About this Report
Verification

4. Governance, Commitments & Engagement
4.1 Governance structure including committees Corporate Governance
Board of Directors
Committee Charters
4.2 Indicate whether chair of highest governance body is also an executive officer Key Facts
Corporate Governance Guidelines
Corporate Governance – Organization
Board of Directors
4.3 Percent of independent directors Corporate Governance Guidelines
Corporate Governance – Board of Directors
4.4 Mechanisms for shareholders and employees to provide recommendations/direction to highest governance body Codes of Conduct
Third Party Standards
Contact Our Directors
Dialogue
4.5 Linkage between compensation and organization’s performance for members of highest governance body/senior executives Corporate Governance Guidelines
Corporate Governance – Compensation and Non-Financial Goals
Compensation and Management Development Committee Charter
4.6 Process for the Board to ensure conflicts of interest are avoided Corporate Governance Guidelines
4.7 Processes for determine qualifications and expertise for guiding strategy Committee on Directors and Corporate Governance
Management System Integration
4.8 Mission and values statements, codes of conduct, principles relevant to economic, environmental and social performance, and status of implementation Codes of Conduct
Third Party Standards
Management Systems
4.9 Procedures of highest governance body for overseeing economic, environmental and social performance including compliance, codes of conduct Corporate Governance - Organization
Organization
Management Systems
Third Party Standards
4.10 Processes for evaluating performance of governance body with respect to economic, environmental and social performance Corporate Governance Guidelines
Management System Integration
4.11 Explanation of how precautionary approach/principle is addressed by organization Systems for Managing Risk
Third Party Standards
4.12 Externally developed, voluntary economic, environmental, and social charters, sets of principles, or other initiatives Overarching Policies– Voluntary standards
4.13 Significant memberships in associations and/or advocacy organizations Stakeholder Engagement– Business association memberships
4.14 List of stakeholder groups Stakeholder Engagement
World Health Organization
Access to Medicines
UN Global Compact
Pharmaceutical Supply Chain Initiative
Together on Diabetes
What We Support
Grants & Giving
Drug Donations and Other Philanthropic Efforts
Disaster Relief & Product Donations
Bristol-Myers Squibb Foundation
Reducing Health Disparities
Cancer in Europe
Hepatitis in Asia
HIV/AIDS Africa
Mental Health in US
Our Partners
Political Contributions
Investor Relations
Our Communities
Worldwide Facilities
Workplace Policies
Bristol-Myers Squibb engages with numerous socially-responsible investment firms and rating organizations to understand and respond to areas of interest, including, but not limited to: Access to Medicines, Bloomberg, Carbon Disclosure Project, Corporate Responsibility, Dow Jones Sustainability Index, EIRIS, Goldman Sachs Sustain, Interfaith Center on Corporate Responsibility, Maplecroft, Newsweek, oekom, and Sustainalytics.
4.15 Basis for identification and selection of stakeholders with whom to engage Stakeholder Engagement
Partnering
Areas of Interest
Our Process
Our Partners
How to Apply for Bristol-Myers Squibb Foundation Grants
Political Contributions
Clinical Research Grants
Corporate Giving
Independent Medical Education
4.16 Approaches to stakeholder engagement, including frequency and type Stakeholder Engagement
4.17 Key issues raised through stakeholder engagement and how organization has responded Position on Key Issues
Stakeholder Engagement

Economic Performance Indicators
Management approach Economic Responsibility– Management Approach
Market Presence
Indirect Benefits
EC1 Direct economic value generated and distributed 2012 Annual Report, pdf pages 29-33 (Consolidated Financial Statements)
2012 Annual Report, pdf pages 49-50 (Fair Value Measurement)
2012 Annual Report, pdf page 55 (Accrued employee compensation and benefits)
Grants & Giving
Economic Performance
Key Performance Indicators
Benefits
Shareholder Value
EC2 Financial implications and other risks and opportunities due to climate change Material issues –Energy and Water
Risk/Opportunity related to Climate Change
EC3 Coverage of the defined benefit plan obligations 2012 Annual Report, pages 58-62 (Pension, Postretirement & Postemployment Liabilities)
EC8 Development and impact of infrastructure investments and services provided for public benefit Philanthropy, Foundation and Corporate Philanthropy
EC9 Indirect impacts Indirect Impacts

Environmental Performance Indicators
Management approach Environmental Performance– Management Approach
Overarching Policies
EN3 Direct energy consumption Direct Energy Consumption (Gigajoules)
Light Fuel Oil
2011: 236,000
2012: 142,000

Natural Gas
2011: 4,109,000
2012: 3,956,000

Propane (LPG)
2011: 273,000
2012: 324,000

Energy Conservation
Sustainability Issues
Energy and Water
Key Performance Indicators
Solar panels installed at our Anagni and Hopewell facilities supply renewable energy. In 2012, we generated 360 gigajoules of energy through these renewable energy sources. Using natural gas, we generated 0.9 million gigajoules of combined steam and electricity at Bristol-Myers Squibb facilities on site in 2012.
EN4 Indirect energy consumption Energy Conservation
Sustainability Issues
Energy and Water
Key Performance Indicators
Greenhouse Gas Emissions
In 2012, our Agen, France facility specified purchase of a certain percentage of energy from their supplier be from renewable sources. This resulted in purchase of 84,500 gigajoules of energy from renewable sources in 2012, out of a total consumption of 11.2 million gigajoules companywide. Amounts of renewable energy sourced from other energy providers are not available at this time.
EN5 Energy saved due to conservation and efficiency improvements Energy Conservation
Sustainability Issues
Energy and Water
EN7 Initiatives to reduce indirect energy consumption Energy Conservation
Sustainability Issues
Energy and Water
EN8 Total water withdrawal Water Use
Sustainability Issues
Energy and Water
Key Performance Indicators
EN9 Water sources significantly affected by withdrawal of water. Water Use
EN13 Habitats protected or restored Biodiversity and Land Use
EN14 Strategies, current actions, and future plans for managing impacts on biodiversity Biodiversity and Land Use
EN16 Direct and indirect greenhouse gas emissions Climate Change and Greenhouse Gas Emissions
Key Performance Indicators
EN17 Other relevant indirect greenhouse gas emissions by weight. Climate Change and Greenhouse Gas Emissions
Key Performance Indicators
EN18 Initiatives to reduce greenhouse gas emissions Climate Change and Greenhouse Gas Emissions
Energy Conservation
EN19 Emissions of ozone-depleting substances Other Air Emissions
EN20 NOx, SOx, and other air emissions Other Air Emissions
EN21 Water discharge Wastewater Effluents
EN22 Waste Waste
Key Performance Indicators
EN23 Significant spills Compliance and Remediation
EN24 Hazardous waste Goals and Key Indicators
EN26 Initiative to mitigate environmental impacts of products Product Stewardship
Wastewater Effluents
EN28 Compliance Compliance and Remediation
EN29 Transport Transportation

Social Performance Indicators
Management approach - LA Social Progress
Management Approach
LA1 Total workforce Diversity and Work/Life Integration
Key Indicators
LA3 Benefits Benefits Program Highlights, Wages and Benefits
LA6 Worker input on health and safety Safety
LA7 Health and safety rates Safety
LA8 Programs to assist employees, families, or community members regarding serious diseases Health and Wellness
Access to Medicines
Help Paying for your Medicines
Bristol-Myers Squibb Foundation
LA11 Skills management and lifelong learning Benefits Listing
Developing our People
Education and Training
LA13 Diversity Diversity and Work/Life Integration
Management approach - HR Suppliers
Workplace Policies
Diversity & Inclusion
Supplier Diversity
Intellectual Property
HR5 Freedom of association Overarching Policies
UN Global Compact
HR6 Operations having significant risk for incidents of child labor Workplace Policies - Labor
HR7 Operations having significant risk for incidents of forced labor Workplace Policies - Labor
Management approach - SO Our Communities
Overarching Policies
Standards of Business Conduct & Ethics
Social Progress
Compliance & Ethics
SO2 Corruption risk Compliance & Ethics
Third Party Standards
SO3 Anti-corruption training Compliance & Ethics
SO5 Public policy development and lobbying Political Contributions
SO6 Total value of contributions to political parties, politicians, and related institutions Political Contributions
SO8 Significant fines/sanctions SEC Filings
EHS Compliance & Remediation
2012 Annual Report, page 65
Management approach – PR Product Responsibility
Data Privacy, page 10
PR1 Product and service health and safety impact assessment Sustainability 2015 Goals
Sharps Management Plan
PR2 Product and service health Clinical Trials Disclosure
PR3 Type of product and service information and safety compliance Products
PR5 Practices related to consumer satisfaction Compliance & Ethics Code
PR6 Program for adherence to laws, standards, and voluntary codes related to marketing communications Product Responsibility
Compliance and Ethics
Compliance & Ethics Code
Endorsement of Pharma Codes/Principles
PR9 Significant fines concerning provision and use of products and services 2012 Annual Report, page 65

Note: In addition to the locations listed in this table, many of the indicators are summarized in the Key Performance Indicators section of this website. For more help in locating sustainability topics, see the site Index.

 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.